A summary of the effects of GLP1, estrogen and a conjugated GLP1-estrogen compound. (a) GLP1 is produced by the gut and acts mainly in the gut, pancreas and brain, increasing insulin sensitivity, and decreasing appetite and gastric emptying. (b) Estrogen is a gonadal steroid hormone with pleiotropic effects, which mainly affects brain function and sexual organs. (c) Finan et al. 1 have now combined estrogen with GLP1 to form a coupled compound that can be specifically taken up by cells that express GLP1 receptor; estrogen then acts through nuclear receptors to mediate its effects. The expression of GLP1 and estrogen receptors in similar areas of the brain makes the GLP1-estrogen compound a more selective therapeutic alternative to estrogen for improvement of the metabolic syndrome without the side effects associated with estrogen therapy in peripheral organs, such as the uterus and breast. health. Night-shift workers are more at risk for obesity, metabolic syndrome and even some forms of cancer 1, 2 , and a decrease in the number of hours slept at night prompts a decrease in insulin sensitivity 3 . Circadian clocks are the main drivers of cyclical changes in biochemical pathways, allowing an organism to be prepared for regular environmental changes. This rhythmicity also has a strong influence on metabolic Most of us have tried to disable our circadian clock mechanisms. For example, when we are desperately trying to meet an important deadline or finish a time-course experiment, we do what it takes to keep us going until the mission is complete. A common strategy involves excessive feeding on comfort foods, as well as a high coffee intake. This is not exactly the hunter-gatherer lifestyle people have been evolutionarily wired for, but it gets us by. Although these short-term fixes are effective, too little sleep or irregular sleep patterns in the long run are associated with serious consequences for 
Metabolic jet lag when the fat clock is out of sync
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There is a growing appreciation of the importance of circadian regulation in energy homeostasis, and the dysregulation of the circadian clock has been associated with obesity and metabolic abnormalities. A new study shows that adipocyte-specific deletion of a core circadian clock gene, Arntl (Bmal1), in mice shifts the timing of their feeding behavior, resulting in obesity (pages 1768-1777).
processes, and we are just starting to understand the underlying mechanisms. A highly conserved set of proteins constitutes the system's circadian machinery. The proteins encoded by the ARNTL and CLOCK genes are at the core of this machinery; they form heterodimers and function as transcription factors that bind to cis-acting E-box elements found in promoters or enhancers of key target genes involved in circadian control. The Cryptochrome (CRY) and Period (PER) genes are the best-characterized downstream transcriptional targets for Clock and Arntl. The Cry and Per proteins also heterodimerize and are part of a negative feedback loop that downregulates Arntl expression. The turnover of these proteins is highly regulated; this, together with the negative feedback loops, result in an oscillating expression pattern over each 24-hour cycle.
The primary circadian 'clock' in mammals is located in the brain, in the suprachiasmatic nuclei, a distinct group of cells located in the anterior hypothalamus. Destruction of the suprachiasmatic nuclei results in the complete absence of a regular sleep-wake rhythm. Surprisingly, endogenous circadian clocks are also found in many peripheral tissues. Thus, there is no such thing as a primary clock in the body; rather, many clocks exist, which communicate through interdependent feedback mechanisms. So far, two metabolically relevant tissues have been targeted for genetic ablation of clock components in mice (Fig. 1) . Lamia et al. 4 disrupted Arntl in hepatocytes; this caused fasting hypoglycemia and enhanced glucose clearance. The authors concluded that hepatic Arntl governs the cyclical expression of biochemical pathways that offset the systemic fluctuations of carbohydrate ingestion at regular meal times. In contrast, Marcheva et al. 5 showed that deletion of Arntl in pancreatic beta cells prompts impaired glucose tolerance due to reduced insulin secretion, and ultimately results in a reduced proliferative potential of pancreatic islets.
In this issue of Nature Medicine, Paschos et al. 6 fill an important gap in our knowledge of circadian control of metabolism by examining the specific role of Arntl in adipocytes and macrophages in mice (Fig. 1) . They found that Arntl could be deleted in macrophages without detectable consequences, but the loss of Arntl in adipocytes (Ad-Arntl −/− mice) affected the circadian rhythm in the brain, thus placing adipocyte Arntl center stage in the control of systemic energy homeostasis.
The authors report that Ad-Arntl −/− mice have an increased expansion of adipose tissue and ultimately develop obesity. These mice display normal circadian rhythms in locomotor activity. However, they have lower energy expenditure and their food intake rhythm is disrupted. These changes do not affect the total number of calories consumed, but the Ad-Arntl −/− mice seem to display the rodent equivalent of 'night eating syndrome': they have a higher food intake during the light phase and compensate with a lower food intake during the dark phase, the main period of food intake and activity in wild-type mice. This is associated with a reduction in total energy expenditure and provides the underlying mechanism for the obese phenotype in these mice. In fact, wildtype mice whose access to food is restricted during the light phase (so they are only allowed to eat during periods of activity at night) are resistant to the negative impacts of a high-fat diet, such as obesity and insulin resistance, despite consuming a similar number of calories to mice on a high-fat diet who do not have restricted feeding times 7 . Thus, the work of Paschos et al. 6 indicates that the circadian clock in adipocytes affects the feeding rhythm of mice, which in turn exerts a profound influence on whole-body energy homeostasis. How is this possible?
Through a series of elegant experiments, the authors provide evidence for a mechanism in which disruption of the circadian rhythm in adipocytes triggers a reduced capacity for synthesis of long-chain polyunsaturated fatty acids (PUFAs) by these cells 6 . Loss of Arntl in adipocytes results in a reduction in the expression of two genes, Elovl6 and Scd1, that encode key enzymes for the biosynthesis of PUFAs. Reduced amounts of these enzymes result in lower plasma concentrations of PUFAs. This effect is further exacerbated by reduced lipolysis at crucial time points during the light phase. As a consequence, the reduced concentrations of circulating PUFAs lead to decreased hypothalamic PUFA concentrations during the light phase. This reduction leads to an upregulation of orexigenic peptides and a downregulation of anorexigenic peptides in the hypothalamus, changes that promote food intake. Of key importance, the authors showed that dietary PUFA supplementation is able to rescue the obesity phenotype of the Ad-Arntl −/− mice.
The Ad-Arntl −/− mice therefore provide strong evidence for the existence of a PUFAmediated communication axis between fat stores and the brain, and they show that changes in the local production and release of these key lipid messengers are sufficient to evoke a profound dysregulation of food intake patterns. The functional consequences of this relatively mild imbalance of the circadian Figure 1 Effects of Arntl knockout in different cell types in mice. Cell type-specific knockouts of Arntl in mice have shown that hepatocytes lacking Arntl fail to adjust to diurnal variability of glucose availability 4 , whereas pancreatic beta cells lacking Arntl show impaired insulin release 5 . Paschos et al. 6 now find that lack of Arntl in adipocytes leads to changes in diurnal food intake patterns due to changes in plasma concentrations of PUFAs, thereby establishing a PUFA-based communication axis between the adipocyte and crucial regulatory centers in the hypothalamus. The net result of this is an overall increase in fat mass and, ultimately, obesity. rhythm in the adipocyte are very surprising and more severe than would be expected given the extent of the disruption. Of further interest, the obese phenotype of the Ad-Arntl −/− mice is not associated with any other signs of impaired metabolic parameters, suggesting that simultaneous protective mechanisms function to allow expansion of fat mass without other adverse metabolic consequences.
The apparently 'healthy' adiposity that is associated with a local disruption of the Arntl in adipocytes deserves further study. What are these additional changes that allow the increased overall fat mass in the Arntl -/-mice? Several candidate mechanisms that enable a fat pad to expand in a nonpathological way-that is, mechanisms that are beneficial for systemic metabolic regulation-have recently been described (reviewed in ref. 8 ). These include reduced fibrosis and improved angiogenesis. Future studies will be required to unveil the crucial components that act locally in adipose tissue in the Arntl −/− mouse model, a mouse that highlights yet another facet of adipocyte physiology. red blood cell and platelet homeostasis, respectively, and they are widely used in the clinic to treat neutropenia, anemia and thrombocytopenia, respectively. The specificity of HGFs is primarily determined by the lineagerestricted expression of their cognate receptors. In addition to stimulating cell proliferation and survival, HGFs may contribute to differentiation and modulate mature blood cell effector functions.
DPP4 is an intrinsic membrane glycoprotein broadly expressed in many tissues-including hematopoietic cells-that is known to cleave bioactive peptides, such as certain chemokines and members of the glucagon-like peptide family. Relevant to hematopoiesis, DDP4 cleaves and inactivates the chemokine CXCL12 (also known as stromal-derived factor-1, SDF-1) 7 , a key component of the stem cell niche required for hematopoietic stem cell maintenance. A study previously showed that DDP4-mediated cleavage of CXCL12 negatively affects the homing and engraftment of hematopoietic progenitors, which can be reversed by treatment with a DPP4 inhibitor 8 .
In the course of their studies on CXCL12 and DPP4, Broxmeyer et al. 3 made a surprising observation-in experimental control cultures stimulated with HGFs alone (that is, containing no CXCL12), inhibition of DPP4
Intensive chemotherapy remains the cornerstone treatment for many types of cancer and is required to ensure engraftment of donor cells after stem cell transplantation. However, a frequent and potentially life-threatening complication of intensive chemotherapy is severe blood cytopenias. Such 'myeloablative' chemotherapy, which depletes bone marrow cells, predisposes patients to higher rates of infection, anemia and bleeding 1 . Indeed, the dose of chemotherapy is limited in many cases owing to the severity of cytopenias, potentially compromising the clearance of cancer cells.
Treatment with certain hematopoietic growth factors (HGFs) can mitigate the severity of cytopenias in some cases. For example, treatment with granulocyte colony-stimulating factor (G-CSF) after chemotherapy reduces the incidence of febrile neutropenia 2 , which is associated with considerable morbidity and mortality. However, despite the use of HGFs, cytopenias after myeloablative chemotherapy remain a major dose-limiting toxicity and source of treatment-related mortality.
New therapies that hasten hematologic recovery after myeloablative chemotherapies are therefore needed.
In this issue of Nature Medicine, Broxmeyer et al. 3 found that dipeptidylpeptidase IV (DPP4 also known as CD26), a peptidase expressed on the cell surface of most hematopoietic cells, cleaves certain HGFs, such as G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF). Cleavage by DDP4 results in the production of truncated growth factors that have markedly reduced ability to induce cell growth and may even act in a dominantnegative action to prevent the activity of fulllength growth factors (Fig. 1) . Suppression of DDP4 activity, genetically or pharmacologically, potentiates the activity of certain hematopoietic growth factors and accelerates hematopoietic recovery after chemotherapy or radiation in mice. Given that US Food and Drug Administration-approved DPP4 inhibitors are available, these findings suggest a new strategy to shorten the duration and magnitude of cytopenias in individuals after myeloablative chemotherapy.
HGFs are secreted glycoproteins that, in many cases, act on a specific blood cell lineage and crucially maintain its homeostasis. In particular, G-CSF 4 , erythropoietin 5 and thrombopoietin 6 are essential for neutrophil,
